Zentalis' Azenosertib Shows 15.8-Month Median Survival in Cyclin E1-Positive Ovarian Cancer
ZNTL sits 74% above its 52-week low of $1.212.
Summary
Zentalis disclosed the first overall survival data for azenosertib from the DENALI Part 1B study, showing a median OS of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer. The results were published in an ESMO Congress 2026 abstract. This is the first hard survival readout for the program and comes as the company pushes toward an accelerated approval path aligned with the FDA, which it outlined alongside Q2 results in August. For a micro-cap biotech trading near $2, the number is the key clinical benchmark investors will weigh against the ovarian cancer standard of care. The August offering raised $75.1 million at $3.50 a share to fund the ovarian cancer development program, and cash was guided to last into late 2027. No OS comparator or statistical detail beyond the 15.8-month median is provided in the release.
At the time of this announcement, ZNTL was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.7M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.